CV: Peter D Walzer MD

Peter D Walzer, MD
Professor of Clinical Medicine
College of Medicine
University of Cincinnati

Practice Address:

Infectious Disease Center - Homes Hospital
Eden and Bethesda Avenues
Cincinnati, OH 45267-0405

Education:

Boston College: B.S.
Albany Medical College: M.D.

Post Graduate Training:

1968-1969 Intern in Medicine, Mary Imogene Bassett Hospital, Cooperstown, New York
1969-1970 Resident in Medicine, Mary Imogene Bassett Hospital, Cooperstown, New York
1970-1972 Epidemic Intelligence Service Officer, Parasitic Diseases Brach, Epidemiology Program, Centers for Disease Control, USPHS, Atlanta, Georgia
1972-1974 Research Associate, Laboratory of Dr. Henry Kunkel, assistant Resident Physician, Rockefeller University, New York, New York
1974-1975 Resident in Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
1975-1976 Fellow in Infectious Diseases, Memorial Sloan-Kettering Cancer Center, New York, New York

Licensure or Certification:

Ohio
New York (inactive)
Georgia (inactive)
Kentucky (inactive)
Diplomate, American Board of Internal Medicine
Diplomate, Subspecialty of Infectious Diseases

Associations:

American College of Physicians
Infectious Disease Society of America
American Federation for Clinical Research
Central Society for Clinical Research
American Society for Microbiology
American Association for the Advancement of Science
American Society for Tropical Medicine and Hygiene
American Society for Parasitologists
American Thoracic Society
Society of Protozoologists
Society for Experimental Biology and Medicine
American Association of Immunologists

Partial List of Publications:

Broomall, K.R., Morris, R.E., Walzer, P.D., Smulian, A.G. Zymolyase treatment exposes p55 antigen of Pneumocystis carinii. J. Euk. Microbio. (in press).
De Stefano, J.A., Meyers, J.D., Du Pont, D., Foy, J.M., Theus., S.A., Walzer, P.D. Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins. J. Euk. Microbio. (in press).
Theus, S.A., Smulian, A.G>, Steele, P., Linke, MJ, Walzer, P.D> Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response in the rat. Vaccine (in press).
Sunkin, S.M., Linke, M.J., McCormack, F.X., Walzer, P.D., Stringer, J.R. Identification of a putative precursor to the major surface glycoprotein of Pneumocystis carinii. Infect. Immun. 1998; 66: 741-746.
Linke, M.J., Andrews, R.A., Walzer, P.D. Expression, Structure, and location of epitomes of the major surface glycoprotein Pneumocystis carinii. Clin Diag Lav Immunol. 1998; 5: 50-57.
Theus, S.A., Sawhney, N., Smulian, A.G., Walzer, P.D. Proliferation and cytokine responses of human T lymphocytes isolated from HIV patients the major surface glycoprotein of Pneumocystis carinii. J Infect. Dis. 1997; 177; 238-241.
Theus, S.A., Walzer, P.D. In vitro cytolytic activity of lymphocytes against Pneumocystis carinii. J. Euk. Microbiol. (supple) 1997; 44: 25-27.
Theus, S.A., Walzer, P.D. Adoptive transfer of specific lymphocyte populations sensitized to the major surface glycoprotein of Pneumocystis carinii decreases organism burden while increasing survival rate in the rat. J. Euk. Microbiol. (sup). 1997; 44: 23-324.
McCormack, F.X., Festa, A.L., Andrew, R.P., Linke, M., Walzer, P.D. The carbohydrate binding domain of surfactant protein: A mediates binding to the major surface glycoprotein of Pneumocystis carinii. Biochemistry. 1997; 36: 8092-8099.
Theus, S.A., Smulian, A.G., Sullivan, D.,Walzer, P.D. Cytokine responses to the native and recombinant forms of the major surface glycoprotein of Pneumocystis carinii. Clin Exper. Immuno. 1997; 109: 255-260.

Hospital Appointments:

Grants:

Veterans Administration Research Grant, Studies of a Major Surface Glycoprotein of Pneumocystis Carinii, 1994-1999. (Principal Investigator)
National Institutes of Health Contract AI-75319, 1997-2002. Pre-clinical Evaluation of Therapies for Pneumocystis carinii Infection. (Principal Investigator)
National Institutes of Health Small Business Innovative Research (SBIR) Grant AI-39315, Targeted Drug Therapy of Pneumocystis carinii Infection. 1996-1997-(Co-Investigator).
National Institutes of Health Contract AI-25139, 1992-1997. Evaluation of Therapies for Treatment of Pneumocystis carinii. (Principal Investigator).
National Institutes of Health Research Grant, RO1-AI-32899, 1992-1995. Surface carbohydrates of Pneumocystis carinii. (Co-Investigator).
National Institutes of Health Research Grant NCDDG UOI AI-31702. 1991-1995. Metabolic Studies of Opportunistic Fungi and Protozoa. (Principal Investigator).
National Institutes of Health Grant NIAID AI-25897, 1987-1995. University of Cincinnati AIDS Study Group. (CO-Investigator).
National Institutes of Health Research Grant, RO1-HL-46653, 1991-1994. Control of Type II Cell Function by Pneumocystis carinii. (Co-Investigator).
National Institutes of Health Mycology Program Project Grant: Molecular and cell Biology of Fungal Pathogens. PO1-AI-28392. 1990-1994. Molecular Genetic Analysis of Pneumocystis. (Co-Investigator).
Veterans Administration Research Grant, 1990-1994. Antigenic Studies of Pneumocystis carinii Infection. (Principal Investigator).